Last reviewed · How we verify

Placebo to ZSP1273

Guangdong Raynovent Biotech Co., Ltd · Phase 3 active Small molecule

Placebo to ZSP1273 is a SGLT2 inhibitor Small molecule drug developed by Guangdong Raynovent Biotech Co., Ltd. It is currently in Phase 3 development for Type 2 diabetes.

ZSP1273 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).

ZSP1273 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.

At a glance

Generic namePlacebo to ZSP1273
SponsorGuangdong Raynovent Biotech Co., Ltd
Drug classSGLT2 inhibitor
TargetSGLT2
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

By inhibiting SGLT2, ZSP1273 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo to ZSP1273

What is Placebo to ZSP1273?

Placebo to ZSP1273 is a SGLT2 inhibitor drug developed by Guangdong Raynovent Biotech Co., Ltd, indicated for Type 2 diabetes.

How does Placebo to ZSP1273 work?

ZSP1273 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).

What is Placebo to ZSP1273 used for?

Placebo to ZSP1273 is indicated for Type 2 diabetes.

Who makes Placebo to ZSP1273?

Placebo to ZSP1273 is developed by Guangdong Raynovent Biotech Co., Ltd (see full Guangdong Raynovent Biotech Co., Ltd pipeline at /company/guangdong-raynovent-biotech-co-ltd).

What drug class is Placebo to ZSP1273 in?

Placebo to ZSP1273 belongs to the SGLT2 inhibitor class. See all SGLT2 inhibitor drugs at /class/sglt2-inhibitor.

What development phase is Placebo to ZSP1273 in?

Placebo to ZSP1273 is in Phase 3.

What are the side effects of Placebo to ZSP1273?

Common side effects of Placebo to ZSP1273 include Increased risk of diabetic ketoacidosis, Genital amputation, Increased risk of acute kidney injury.

What does Placebo to ZSP1273 target?

Placebo to ZSP1273 targets SGLT2 and is a SGLT2 inhibitor.

Related